PneumomAb

PneumomAb is a monoclonal antibody developed for the treatment and prevention of pneumococcal disease caused by **Streptococcus pneumoniae**. It targets pneumococcal surface proteins or polysaccharides to neutralize bacterial pathogens via opsonophagocytic activity and complement-mediated killing, offering potential as a therapeutic for invasive pneumococcal infections in high-risk populations such as immunocompromised patients or those with pneumonia. The developer and specific clinical status remain undisclosed in available data, distinguishing it from prophylactic pneumococcal vaccines like PCV21 or PPSV23[1][2][3].